🧫
Ex vivo IGF-I treatment in rd10 organotypic retinal explants
active
experiment
Created: 2026-04-10T22:34:11
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-da891eb0-f020-4272-b989-5c591be77c9d
🧫 Experiment Protocol
Validationretinitis pigmentosaPde6brd10 mouse organotypic retinal explantsproposed
Organotypic retinal explants from Pde6b(rd10) mice were treated with IGF-I to assess neuroprotective effects on photoreceptor cell death. The study evaluated cell death using TUNEL staining and ELISA of free nucleosomes, while monitoring microglial cell distribution using Cd11b and Iba1 immunolabeling. Microglia were depleted using clodronate-containing liposomes to determine their role in IGF-I-mediated neuroprotection. Results showed that IGF-I treatment reduced TUNEL-positive nuclei and increased microglial cells in the outer nuclear layer (ONL). Microglial depletion diminished IGF-I's neuroprotective effect but also moderately reduced baseline photoreceptor death.
PRIMARY OUTCOME
photoreceptor cell death reduction
EXPECTED OUTCOMES
IGF-I treatment would reduce photoreceptor cell death and modulate microglial response
SUCCESS CRITERIA
Reduction in TUNEL-positive nuclei and free nucleosome levels
PROTOCOL
Organotypic retinal explants treated with IGF-I, cell death assessed by TUNEL staining and ELISA of free nucleosomes, microglial visualization by Cd11b and Iba1 immunolabeling, microglial depletion with clodronate liposomes
Source: PMID 22039242 ↗
🧫 Experiment Extras
PATHWAY
IGF-I signaling pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.